Operational Excellence: More Data or Smarter Approach? - The authors focus on operational excellence in manufacturing of biotechnology therapeutic products in the QbD paradigm. - BioPharm

ADVERTISEMENT

Operational Excellence: More Data or Smarter Approach?
The authors focus on operational excellence in manufacturing of biotechnology therapeutic products in the QbD paradigm.


BioPharm International
Volume 24, Issue 6, pp. 36-41

CONCLUSION

This article aims to illustrate the need to achieve operational excellence with respect to data- and knowledge-management systems to successfully implement QbD for manufacturing of biotherapeutics. As discussed, there is a great need among the biomanuacturing industry to apply risk-assessment and management principles to achieve this objective. When done correctly, this approach is more economical and effective than traditional approaches otherwise used in industry.

Anshuman Bansal, PhD, and Jaspinder Hans are cofounders of Simplyfeye Softwares in Delhi, India. Anurag Rathore, PhD, is a partner at Simplyfeye and a faculty member at the Indian Institute of Delhi, India, +91-9650770650,
. Rathore is also a member of BioPharm International's editorial advisory board.

REFERENCES

1. "Operational excellence" as defined by Industry Week, http://www.industryweek.com/articles/operational_excellence_defined_14011.aspx

2. ICH, Q8(R1): Pharmaceutical Development, November, 2008.

3. A.S. Rathore and H. Winkle, Nature Biotechnology, 27 (1) 26–34 (2009).

4. A.S. Rathore, Trends in Biotechnol. 27 (9) 546–553 (2009).

5. R. Johnson et al., BioPharm. Intl., 20 (10) 130–144 (2007).

6. P. Konold, R. Woolfenden II, Cenk Undey, and A. S. Rathore, BioPharm. Intl. 22 (5) 26–39 (2009).

See the full list of articles within this series.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here